From Crisil rating update report released yesterday link
“The group plans to incur a capital expenditure (capex) of ~Rs 250 crore over fiscals 2025 and 2026 to expand capacity in its gelatin and collagen peptide unit. It has announced withdrawal of its proposed rights issue of Rs 40 crore to fund the above capex and plans to finance the proposed investment through a mix of internal accrual and external borrowings. Though this could be partly debt-funded, financial risk profile is projected to remain comfortable on the back of expected annual cash accrual of over Rs 50 crore and adequate liquid surplus, which stood at Rs 76 crore as of March 31, 2024.”
| Subscribe To Our Free Newsletter |
